logo-loader
viewActinogen Medical Ltd

Actinogen Medical Ltd to enhance safety profile of Alzheimer’s drug study

au_drug_research_358.jpg

Actinogen Medical Ltd (ASX:ACW) is making progress in its Phase II clinical trial of its promising new Alzheimer’s drug Xanamem after discussions with the U.S. FDA.

The company is seeking FDA approval under an Investigational New Drug (IND) for the Phase II study of the drug.

The company is interacting with the U.S. FDA to enhance the safety profile of XanADu, their pivotal global Phase II clinical trial investigating Xanamem.

An enhanced protocol will be detemined with both Australian and U.K. regulators and hospital sites, with patients expected to be enrolled in the second half of 2016.

Importantly, a U.S. focused study and protocol design will allow for broader value creation, as the U.S. is the largest market for Alzheimer’s drugs.

Xanamem has been specifically designed to inhibit the excess production of cortisol, the ‘stress hormone’ in the brain.

Recent global research has demonstrated that excess cortisol is associated with cognitive decline and neurotoxicity in the brain, which are the hallmarks of Alzheimer’s disease.

In 2015 the total estimated global cost of treating Alzheimer’s was close to US$1 trillion.

The potential upside for a successful drug is significant, which has helped Actinogen share price almost double during the last six months.

The phase II study is fully funded through to completion with $6.8 million cash as on 31 March 2016.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Actinogen Medical Ltd

Price: 0.035 AUD

ASX:ACW
Market: ASX
Market Cap: $39.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bull, Bears & Brokers: Shaw and Partner’s Davide Bosio talks about market...

Shaw and Partners WA state manager Davide Bosio updates Proactive on how share prices plunged this week, with stock market jitters in light of the coronavirus scare. Bosio gives his advice on how investors can protect their portfolios and takes a look at solid investment options during times...

9 hours, 20 minutes ago

2 min read